ArticleEMBO molecular medicine2024
DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer.
Majid Momeny et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this papertrialcites it